INVESTOR PRESENTATION - VIFOR PHARMA

Page created by June Rivera
 
CONTINUE READING
INVESTOR PRESENTATION - VIFOR PHARMA
PRESENTATION

               VIFOR PHARMA
               INVESTOR PRESENTATION

               December 2018
INVESTOR PRESENTATION - VIFOR PHARMA
VIFOR PHARMA
OUR VISION

                           Global Leader
                  in Iron Deficiency, Nephrology
                   and Cardio-Renal Therapies.

© Vifor Pharma   December 2018                     2
INVESTOR PRESENTATION - VIFOR PHARMA
EXPERIENCED LEADERSHIP TEAM
PROVEN TRACK RECORD

            ETIENNE JORNOD          STEFAN SCHULZE                COLIN BOND
        EXECUTIVE CHAIRMAN       PRESIDENT OF THE EXECUTIVE   CHIEF FINANCIAL OFFICER
    OF THE BOARD OF DIRECTORS         COMMITTEE & COO

© Vifor Pharma   December 2018                                                          3
INVESTOR PRESENTATION - VIFOR PHARMA
PROVEN TRACK RECORD
CORPORATE TIMELINE AND STRATEGY
                                                                                                                        2020
                                                                                     2015
                                     2010
2000                                                                                    BECOMING GLOBAL LEADER
                                                                                        IN NEPHROLOGY AND ENTERING
                                            BECOMING GLOBAL LEADER
                                                                                        CARDIO-RENAL DISEASE AREA
 BUILDING IRON PORTFOLIO                    IN IRON DEFICIENCY AND
 AND INTERNATIONAL EXPANSION                ENTERING INTO NEPHROLOGY                    • 2015: Mircera® License

 • 2000: Venofer® US FDA approval                                                       • 2015: Veltassa® License
                                            • 2010: Creation of VFMCRP                  • 2016: Four Licensing Deals
 • 2007: Launch of     Ferinject®
                                            • 2013:   Injectafer®   – FDA approval      • 2016: Relypsa Acquisition
 • 2008: Acquisition Aspreva
                                            • 2013: Launch of Velphoro®                 • 2017: Galenica Santé IPO
 • 2008: Creation of EU affiliates
 • 2009: Acquisition OM Pharma                                                          • 2017: Vadadustat License
                                                                                        • 2017: Veltassa® EU approval
                                                                                        • 2017: Mircera® license expansion
                                                                                        • 2018: CR845 License

© Vifor Pharma   December 2018                                                                                               4
INVESTOR PRESENTATION - VIFOR PHARMA
LEADING PORTFOLIO IN TARGET DISEASE AREAS

                                                  Iron
                                                            Nephrology                     Cardio-Renal
                                               Deficiency

   Own
 Products

 In-licensed
                                                                 Avacopan1)     CCX1401)
  Products                                                  1)

                                                                 Vadadustat1)   CR8451)

1) Pre-commercial   products

© Vifor Pharma                 December 2018                                                              5
THREE STRATEGIC GROWTH DRIVERS

                    Ferinject®
                    Exploit the Potential through Market Awareness

                    Vifor Fresenius Medical Care Renal Pharma
                    Grow and Enhance Value

                    Veltassa®
                    Build a Blockbuster

© Vifor Pharma   December 2018                                       6
FERINJECT®
SIGNIFICANT MARKET OPPORTUNITY REMAINS 1)
                                        Ferinject® In-Market Volume Growth                                   Ferinject® Volume Per Capita2)
                                                                                                                                                Launch Date

                                                                                  5%           Switzerland                                    253   2008

                                                              33%                                Australia                            107           2011

                                               47%                                            New Zealand                        51                 2012

                                                                          16%                    Sweden                     36                      2008

                                                                          16%                   Germany                     34                      2007

                                                        39%                                       Spain                 29                          2009

                                                                          16%                     France               22                           2011

                                                                    22%                             UK                 22                           2008

                                            53%                                                    Italy               22                           2012

                                                  45%                                              U.S.           12                                2013

                                                                                       0%         Japan       0                                     2019

                                                                                       0%         China       0                                     2021
1) Based   on Quarterly IQVIATM MIDAS® panel, GERS, Insight Health, Moving Annual Total (MAT) Q2 2017-18
2)   100 mg eq./1’000 population

© Vifor Pharma              December 2018                                                                                                                  7
FERINJECT®
A BLOCKBUSTER BY 2020
FERINJECT   ® IN-MARKET
GLOBAL I.V. IRON             Q2 1)2018)
                         SALES
                 MARKET (MAT       (MCHF)
                                       1)                                                                                                                     IN-MARKET SALES1)
                                                                                                                                                              CHF MILLION
• Market totalled CHF 1’698 million, +15% versus prior year period
• Ferinject® growth represented 88% of the total market growth, with +32% versus prior year period                                                                                 850-880
• Global market share of              Ferinject®      in value is 47% (54% in our top 10 markets)
                                                                                                                                                                      692
                                                                                                                                                         535
                                                                                                                                    374
                                                                                                                         240
                                                                                  123                 163
                                           58                  81
    16                  38

   2008                 2009               2010               2011                2012                2013                2014      2015                  2016         2017         2018E2)

  Launch in           FAIR-HF          FERGI-COR                            PREFER study           FIND-CKD            CONFIRM-   New EU               New ESC      Intensifying   PIVOTAL
  CH, UK,             study            study                                (fatigue)              study (ND-          HF study   onco                 guidelines   promotional    study
  Spain               (cardio)         (gastro)                                                    CKD)                (cardio)   guidelines           (cardio)     effort by      (Dialysis)
                                                                            New EU
                                                                                                                                                                    Daiichi
                                                                            guidelines:            Injectafer®                                         EFFECT-HF
                                                                                                                                                                    Sankyo
                                                                            nephro, cardio,        approved                                            study
                                                                            gastro, onco           in the USA                                          (cardio)

  Europe         US     ROW
MAT = Moving annual total
1) Based on Quarterly IQVIATM MIDAS® panel, GERS, Insight Health, DLI, historical data at constant exchange rate (average 2017)    2) Estimate based   on IQVIATM

© Vifor Pharma             December 2018                                                                                                                                                        8
FERINJECT®
THE BLOCKBUSTER PLAN

     Therapeutic                 • Heart Failure              Strong         • Partnering with leading
     areas with high             • Gastroenterology           partnerships     companies in and outside
     unmet need                                                                of Europe
                                 • Nephrology
                                 • Patient Blood Management

     Geographic                  • Japan (2019)               Life Cycle     • AFFIRM-AHF
     expansion                   • China (2021)               Management     • HEART-FID
                                 • Key pharmerging markets

© Vifor Pharma   December 2018                                                                            9
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
THE RATIONALE

                                                                            55% Stake
           STRONG IRON AND PHARMA EXPERTISE

                                                            1)

                                                                 CCX1401)

                                                           Avacopan1)

                                               CR8451)   Vadadustat1)

                      GLOBAL LEADER IN DIALYSIS

                                                                            45% Stake

1) Pre-commercial   products

© Vifor Pharma                 December 2018                                            10
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
SYNERGISTIC PARTNERSHIP
                                                                                                           55% Stake

               STRONG IRON AND PHARMA EXPERTISE
                              Sourcing of innovation
                          Evaluation of clinical assets
                           Acceptance of clinical risk
               Regulatory and market access expertise                                                  Focus on pharma needs of nephrology patients – Global Leader
                                                                                                            Access to patient data. Faster clinical trial execution
                                                                                                                        Faster uptake and utilisation

                       GLOBAL LEADER IN DIALYSIS
                                                                                                             Partnership technically controlled by Vifor Pharma
                             Managed care expertise
                      Patient access (>300k patients)
                             Validation of innovation
             Medications in FKC clinics1) become SoC2)
                                                                                                            45% Stake
1) Fresenius  Kidney Care (FKC): Fresenius Medical Care North America dialysis provider organization
2)   Standard of care
© Vifor Pharma               December 2018                                                                                                                            11
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
CURRENT PORTFOLIO

       ANAEMIA                                 MINERAL & BONE     KIDNEY     CKD-ASSOCIATED   CARDIO-RENAL
     MANAGEMENT                                 MANAGEMENT      PROTECTION   COMPLICATIONS    MANAGEMENT

                                                                Avacopan1)      CR8451)

                                                                 CCX1401)

                                                           1)

    Vadadustat1)
1) Pre-commercial   products

© Vifor Pharma                 December 2018                                                                 12
NEPHROLOGY
LEADERSHIP ON THE WHOLE NEPHROLOGY CHAIN

                 PRE CLINICAL                 CLINICAL / PRE-COMMERCIAL

                 PARTNERSHIP             IN-LICENSING DEALS AND PARTNERSHIPS

                                                     Avacopan

                                                                                  DATA GENERATION
                                    CCX140
                                             CR845          Vadadustat

                                      COMMERCIAL

                 PRE DIALYSIS           DIALYSIS                TRANSPLANTATION

© Vifor Pharma      December 2018                                                                   13
VELTASSA®
OVERVIEW OF KEY FEATURES

                   Mode of action                   High safety profile
             Calcium-based, non-absorbed         Limited undesirable effects

                   52-weeks data                         RAASi enabling
                 AMETHYST-DN study                  Included in SmPC1) in Europe

                               Broad use          Room temperature storage
                            Acute & Chronic       US: 3 months / EU: 6 months

1) SmPC   = summary of product characteristics

© Vifor Pharma              December 2018                                          14
VELTASSA®
ADDRESSES LIFE THREATENING UNMET MEDICAL NEED
  MORTALITY AND CARDIAC ARREST IN IN-HOSPITAL EVENTS VS SERUM K+                                               DISEASE BACKGROUND

                                                Hypokalemia             Normal              Hyperkalemia        Prevalent in CKD and CHF
                                                                                                                 patients
                                          60
                                                                                                       Death
                                                                                                                Asymptomatic
                 in-hospital events (%)
                    AMI patients with

                                                                                                                Inhibits use of renin
                                                                                                                 angiotensin aldosterone
                                                                                                                 inhibitors (RAASi)

                                                                                                                Disease awareness is
                                                                                                                 underdeveloped
                                          0
                                                      3.0     3.5     4.0     4.5     5.0       5.5

                                                  Post admission serum potassium level (mean, mEq/L)

© Vifor Pharma                             December 2018                                                                                    15
VELTASSA® U.S. RAMP-UP
KEY CONSIDERATIONS
 3 MILLION HYPERKALEMIA PATIENTS IN THE U.S.                                                    U.S. MARKET OPPORTUNITY

                                                                                                • 3 million potential patients
                            12
                                 10.7                                                           • Gross price of USD 820 per month
                            10                                                                  • Targeted duration of treatment: 6 months
                                                                                                • 10% treated with Veltassa®
    Patients (in million)

                             8
                                                                                                = USD 1 billion in net sales (blockbuster)
                             6
                                                          4.7
                                                                                                Key drivers of success:
                             4
                                                                                                • Awareness                ✓
                                                                               2.3
                             2             1.7                                                  • Access                   ✓
                                                                  0.8
                                                                                          0.5   • Duration of treatment    ✓
                             0
                                 CKD 3-4 only           CKD 3-4 with HF             HF only     • Coverage                 ✓
                                            Total Prevalence    With hyperkalemia

Source: USRDS 2013 ADR, CDC

© Vifor Pharma                          December 2018                                                                                        16
VELTASSA®
TOTAL US DEMAND PER BUSINESS DAY (BD)

                                 •   Demand growth: +81% year over year
                           700
                                 •   Global net sales: CHF 36.8 million (+51.8%) in H1 2018
                           600
                                 •   88% of lives covered, Medicare coverage increased to 64%
                                 •   Amber study expected to be completed in 2018
   Demand (boxes) per BD

                           500

                           400

                           300

                           200

                           100

                             0

© Vifor Pharma                       December 2018                                              17
R&D INVESTMENTS
“MILESTONE 2020” STRATEGIC PLAN

                                            PHASE 1                            PHASE 2                              PHASE 3                COMMERCIAL                              PHASE 4

                                                                                                                                                                              AFFIRM-AHF
                                     Ferroportin inhibitor1)             2019

        Own
      Products                                                                                                                                                                Paediatric
                                                                                                                                                                              AMBER
                                                                                                                                                                              DIAMOND
                                                                                                                                              Anti-infectives

   In-licensed                                                                                                                           2019
    Products
                                                                                                                     Avacopan            20192)
                                                                                CCX140
                                                                                                                   Vadadustat3)
                                                                                                                       CR845

1) Iron   overload; leveraging iron metabolism expertise   2)   Earlier launch possible due to EMA conditional marketing approval   3)   Filing expected by the end of 2019

© Vifor Pharma                 December 2018                                                                                                                                                 18
FINANCIAL HIGHLIGHTS 1)

                          NET SALES                                                                       EBITDA                                                  FERINJECT®/INJECTAFER®

                  +23.4%                                                                     +44.5%                                                                  +29.3%
                         CORE EPS2)                                                    NET DEBT (in million CHF)                                                       EQUITY RATIO

                           2.66                                                                    127.5                                                              80.0%
1) Half-year results 2018
2)   Reported earnings after minorities adjusted for amortisation of intangible assets to normalise for the significant impact from the acquisition of Relypsa.

© Vifor Pharma                 December 2018                                                                                                                                               19
GUIDANCE 2018
NET SALES AND EBITDA GUIDANCE INCREASED

                 In 2018 at constant exchange rates Vifor Pharma net sales are expected to grow
                 by more than 15% and reported EBITDA by more than 25%.
                 In 2020 net sales are expected to exceed CHF 2 billion and EBITDA to reach a high triple-digit
                 level.
                 For 2018 and 2019, the dividend is expected to be at the same level as for 2017. From 2020
                 onwards, the payout ratio is targeted at 35% of net income.

© Vifor Pharma        December 2018                                                                               20
OUTLOOK 2018

  PRODUCT                                 Veltassa® commercial launch in key European countries
  LAUNCHES                                Avacopan CMA1) approval in Europe late 2018/early 2019

                                          Veltassa® partnering in Japan
  PARTNERING
                                          Partnering the Japanese rights for CCX 140

  IN-LICENSING                                Completion of one additional in-licensing deal during the course of 2018

                                          Veltassa®: completion of the AMBER study for treatment of patients with resistant hypertension
  CLINICAL                                Veltassa®: initiation of the DIAMOND outcome study for RAASi enabling
                                          Ferroportin inhibitor: completion of phase-I study
1) Conditional   Marketing Approval

© Vifor Pharma               December 2018                                                                                                  21
CONTACT INFORMATION

                           Colin Bond – CFO
                           Phone:    +41 58 851 83 53
                           Email:    colin.bond@viforpharma.com

     INVESTOR RELATIONS

                           Julien Vignot
                           Phone:    +41 58 851 66 90
                           Email:    julien.vignot@viforpharma.com

                           Laurent de Weck
                           Phone:    +41 58 851 80 95
                           Email:    laurent.deweck@viforpharma.com

© Vifor Pharma   December 2018                                        22
DISCLAIMER

Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as
appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward-
looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to
differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude
of factors including, but not limited to, changes in demand, competition and technology, can cause actual events,
performance or results to differ significantly from any anticipated development. Forward-looking statements contained
in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities
will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update
or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change
in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the
Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person’s
officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors
nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this
presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-
looking statements, which speak only as of the date of this presentation.

© Vifor Pharma   December 2018                                                                                                23
You can also read